{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE335nnn/GSE335831/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE335831"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance","description":"We conducted single-cell RNA sequencing using the 10x Genomics Chromium Next-GEM Flex protocol to investigate the mechanism of action behind the improved therapeutic efficacy of anti-CTLA4 seen when combined with FcgrII blockade. Our goal was to understand the mechanism of action of the combination of anti-CTLA4 and anti-FcgrII in comparison to anti-CTLA4 single treatment. These studies provide new insights and role of FcgrII blockade as therapeutic target in cancer.","dates":{"publication":"2026/07/29"},"accession":"GSE335831","cross_references":{"GSM":["GSM9821783","GSM9821782","GSM9821781","GSM9821784"],"GPL":["24247"],"GSE":["335831"],"taxon":["Mus musculus"],"PMID":["[42522039]"]}}